Biochemical mechanisms underlying MPTP-induced and idiopathic parkinsonism. new vistas
Singer, T.P.; Ramsay, R.R.; Sonsalla, P.K.; Nicklas, W.J.; Heikkila, R.E.
Advances in Neurology 60: 300-305
1993
ISSN/ISBN: 0091-3952 PMID: 8380523 Document Number: 413280
Document emailed within 1 workday
Related Documents
Blanchet, P.J.; Gomez-Mancilla, B.; Bédard, P.J. 1995: DOPA-induced "peak dose" dyskinesia: clues implicating D2 receptor-mediated mechanisms using dopaminergic agonists in MPTP monkeys Journal of Neural Transmission. Supplementum 45: 103-112Gaspo, R.; Bosch, R.F.; Talajic, M.; Nattel, S. 1997: Functional mechanisms underlying tachycardia-induced sustained atrial fibrillation in a chronic dog model Circulation 96(11): 4027-4035
Luthman, J.; Jonsson, G. 1986: Effects of the parkinsonism-inducing neurotoxin MPTP and its metabolite MPP+ on sympathetic adrenergic nerves in mouse iris and atrium Medical Biology 64(2-3): 95-102
Wang, M.-x.; Zhao, J.-y.; Sun, D.-m.; Meng, X.-b.; Sun, G.-b.; Sun, X.-b. 2016: Protective effects and underlying mechanisms of Panax notoginseng saponins against SH-SY5Y cell apoptosis induced by 6-hydroxydopamine Yao Xue Xue Bao 51(6): 898-906
Horský, J.; Krs, O.; Bielavský, J. 1990: Role of interaction of the tanycytes of the third ventricle of the brain with the vascular bed endothelium in enzymatic activation of the parkinsonism-inducing proneurotoxin MPTP in rat brain Folia Morphologica 38(1): 24-27
Rainsford, K.D. 1989: The biochemical protective mechanisms against non-steroidal anti-inflammatory drug induced G-i mucosal damage Acta Physiologica Hungarica 73(2-3): 261-278
Teychenne, P.F.; Leigh, P.N.; Reid, J.L.; Calne, D.B.; Greenacre, J.K.; Petrie, A.; Bamji, A.N. 1975: Idiopathic parkinsonism treated with bromocriptine Lancet 2(7933): 473-476
Calne, S. 1994: Examining causes and care of idiopathic parkinsonism Nursing Times 90(16): 38-40
Laplante, M.; Tran-Manh, N. 1973: Etiology and pathogenesis of idiopathic Parkinsonism: a model Agressologie: Revue Internationale de Physio-Biologie et de Pharmacologie Appliquees Aux Effets de l'Agression 14(5): 287-307
Calne, S. 1994: Nursing care of patients with idiopathic parkinsonism Nursing Times 90(24): 38-39
Löschmann, P.A.; Lange, K.W.; Wachtel, H.; Turski, L. 1994: MPTP-induced degeneration: interference with glutamatergic toxicity Journal of Neural Transmission. Supplementum 43: 133-143
Chan, P.; Di Monte, D.A.; Langston, J.W.; Janson, A.M. 1997: (+)MK-801 does not prevent MPTP-induced loss of nigral neurons in mice Journal of Pharmacology and Experimental Therapeutics 280(1): 439-446
Viaggi, C.; Vaglini, F.; Pardini, C.; Sgadò, P.; Caramelli, A.; Corsini, G.U. 2007: CYP 2E1 mutant mice are resistant to DDC-induced enhancement of MPTP toxicity Journal of Neural Transmission. Supplementum 2007(72): 159-163
Heilman, K.M.; Watson, R.T. 1977: Mechanisms underlying the unilateral neglect syndrome Advances in Neurology 18: 93-106
McNeilly, A.S.; Tay, C.C.; Glasier, A. 1994: Physiological mechanisms underlying lactational amenorrhea Annals of the new York Academy of Sciences 709: 145-155
Levitskaia, N.G.; Sebentsova, E.A.; Andreeva, L.A.; Alfeeva, L.I.; Kamenskiĭ, A.A.; Miasoedov, N.F. 2002: Neuroprotective effects of semax in MPTP-induced disturbances of brain dopamine system Rossiiskii Fiziologicheskii Zhurnal Imeni I.M. Sechenova 88(11): 1369-1377
Zhou, J.; Duan, L.-p.; Yang, X.-l.; Dong, X.-y.; Lin, S.-r. 2003: The roles of dopamine 4 receptor in MPTP-induced gastrointestinal mucosal injury in rats Zhonghua Yi Xue Za Zhi 83(18): 1611-1614
Pincelli, C.; Schafer, P.H.; French, L.E.; Augustin, M.; Krueger, J.G. 2018: Mechanisms Underlying the Clinical Effects of Apremilast for Psoriasis Journal of Drugs in Dermatology: Jdd 17(8): 835-840
Kohl, R.L.; Lewis, M.R. 1987: Mechanisms underlying the antimotion sickness effects of psychostimulants Aviation Space and Environmental Medicine 58(12): 1215-1218
Zeevalk, G.D.; Nicklas, W.J. 1991: Mechanisms underlying initiation of excitotoxicity associated with metabolic inhibition Journal of Pharmacology and Experimental Therapeutics 257(2): 870-878